from ~45% earlier. R&D; spend relates to developing complex/specialty generics including (1) difficult formulation technologies (liposomes/nanoparticles/microspheres), (2) difficult tosynthesise/scale up (peptides, heparins, chiral chemistry), (3) differentiated delivery...